Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 7/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817793 | 0.88 | CNR1 (0.54) | CNR1MAPTOPRK1HPGD | |
| SCHEMBL3818182 | 0.88 | CNR1 (0.52) | CNR1MAPTHPGDALDH1A1 | |
| SCHEMBL3813241 | 0.85 | THRB (0.45) | CNR1MAPTNAMPTTHRBGRIA1 | |
| SCHEMBL2702944 | 0.85 | THRB (0.45) | CNR1MAPTNAMPTTHRBGRIA1 | |
| SCHEMBL2703114 | 0.83 | CNR2 (0.46) | CNR1NAMPT | |
| SCHEMBL2704721 | 0.80 | CNR1 (0.45) | CNR1NAMPT | |
| SCHEMBL2704723 | 0.80 | CNR1 (0.45) | CNR1NAMPT | |
| SCHEMBL27899137 | 0.78 | NAMPT (0.43) | CNR1NAMPT | |
| SCHEMBL12099824 | 0.76 | NAMPT (0.58) | MAPTNAMPT | |
| SCHEMBL2704105 | 0.76 | MAPT (0.46) | CNR1MAPTHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101522644-B | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators | HOFFMANN LA ROCHE | 2013-04-24 | — | — | CN | disclosed |
| EP-2074096-B1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8188093-B2 | Pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2450350-A1 | 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | F. Hoffmann-La Roche AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | ANDJELKOVIC MIRJANA | 2010-10-21 | — | — | US | disclosed |
| US-7812028-B2 | 3-pyridinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2076499-B1 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-7691863-B2 | Pyrazine-2-carboxamide derivatives as CB2 receptor modulators | HOFFMAN-LA ROCHE INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2076499-A2 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| EP-2074096-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | ANDJELKOVIC MIRJANA | 2009-06-04 | — | — | US | disclosed |
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
| US-20080085905-A1 | Pyrazine-2-carboxamide derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
| WO-2008040649-A2 | PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040651-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | CETP, APOB, LDLR | CNR1 69/4885MAPT 4139/4885NAMPT 2091/4885 |
| US-20080085905-A1 | Pyrazine-2-carboxamide derivatives | CNR2, CNR1, P2RY2 | CNR1 2/4885MAPT 3285/4885NAMPT 1590/4885 |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | CETP, APOB, LDLR | CNR1 69/4885MAPT 4139/4885NAMPT 2091/4885 |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | CETP, APOB, LDLR | CNR1 69/4885MAPT 4139/4885NAMPT 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.